Carsten Rose

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials
    Carsten Rose
    Department of Oncology, Lund University Hospital, 22185 Lund, Sweden
    J Cancer Res Clin Oncol 134:7-17. 2008
  2. ncbi An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole
    C Rose
    Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden
    Eur J Cancer 39:2318-27. 2003
  3. ncbi Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort
    Andrea Markkula
    Department of Oncology, Skane University Hospital, Lund, Sweden
    Cancer Prev Res (Phila) 5:735-45. 2012
  4. ncbi Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort
    Andrea Markkula
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Cancer Causes Control 23:1307-16. 2012
  5. ncbi A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer
    Carsten Rose
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Am J Clin Oncol 26:S9-16. 2003
  6. ncbi Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden
    Maria Hietala
    Department of Oncology, Clinical Sciences, Lund University, Sweden
    Acta Oncol 50:134-43. 2011
  7. ncbi Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
  8. ncbi Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status
    Erika Bågeman
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Cancer Epidemiol Biomarkers Prev 17:895-901. 2008
  9. ncbi A systematic overview of radiation therapy effects in breast cancer
    Lars Erik Rutqvist
    Department of Oncology, Huddinge University Hospital, Stockholm, Sweden
    Acta Oncol 42:532-45. 2003
  10. ncbi CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients
    H Jernstrom
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund SE 221 85, Sweden
    Br J Cancer 101:1817-23. 2009

Collaborators

Detail Information

Publications18

  1. ncbi Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials
    Carsten Rose
    Department of Oncology, Lund University Hospital, 22185 Lund, Sweden
    J Cancer Res Clin Oncol 134:7-17. 2008
    ..The results of these trials have important clinical implications for the future of extended adjuvant hormonal therapy for breast cancer...
  2. ncbi An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole
    C Rose
    Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden
    Eur J Cancer 39:2318-27. 2003
    ..These results support previous data documenting the greater aromatase-inhibiting activity of letrozole and indicate that advanced breast cancer is more responsive to letrozole than to anastrozole as second-line endocrine therapy...
  3. ncbi Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort
    Andrea Markkula
    Department of Oncology, Skane University Hospital, Lund, Sweden
    Cancer Prev Res (Phila) 5:735-45. 2012
    ..97; 95% CI, 1.08-8.15), adjusted for age and tumor characteristics. In conclusion, two clinical profiles predicted early nonadherence and may allow for targeted interventions to increase adherence if validated in an independent cohort...
  4. ncbi Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort
    Andrea Markkula
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Cancer Causes Control 23:1307-16. 2012
    ..The purpose of this study was to elucidate whether breast size independently influenced disease-free survival in breast cancer patients...
  5. ncbi A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer
    Carsten Rose
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Am J Clin Oncol 26:S9-16. 2003
    ..Based on favorable results from these trials, letrozole and anastrozole have also been approved for use as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer...
  6. ncbi Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden
    Maria Hietala
    Department of Oncology, Clinical Sciences, Lund University, Sweden
    Acta Oncol 50:134-43. 2011
    ..We studied biologically based CAM use with and without vitamins/minerals in relation to patient and tumor characteristics as well as treatment in an ongoing prospective cohort of 855 primary breast cancer patients...
  7. ncbi Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
    Quinci Romero
    Department of Oncology, Skane University Hospital, Lund, Sweden
    BMC Cancer 11:341. 2011
    ..Also, a lack of consensus concerning Ki67 assessment may raise problems in the comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment...
  8. ncbi Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status
    Erika Bågeman
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Cancer Epidemiol Biomarkers Prev 17:895-901. 2008
    ..2; 95% confidence interval, 1.9-9.3; P = 0.0002). These findings raise the hypothesis that coffee slows the growth of ER-positive tumors in patients with CYP1A2*1F A/A and may have implications for breast cancer if confirmed...
  9. ncbi A systematic overview of radiation therapy effects in breast cancer
    Lars Erik Rutqvist
    Department of Oncology, Huddinge University Hospital, Stockholm, Sweden
    Acta Oncol 42:532-45. 2003
    ..There is insufficient evidence to define the optimal integration of systemic adjuvant therapy and postoperative radiotherapy. There are limited data on radiotherapy-related morbidity in breast cancer. No conclusions can be drawn...
  10. ncbi CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients
    H Jernstrom
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund SE 221 85, Sweden
    Br J Cancer 101:1817-23. 2009
    ..We aimed to investigate the frequency of CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival...
  11. ncbi Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women
    E Bågeman
    Department of Oncology, Clinical Sciences, Lund University, SE 221 85 Lund, Sweden
    Br J Cancer 96:712-7. 2007
    ..006). Multiparity combined with IGF1-19/-19 was associated with an early age at breast cancer diagnosis. If confirmed, IGF1-19/-19 may help identify a subgroup of women for earlier breast cancer screening...
  12. ncbi Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)
    L Beex
    Department of Medical Oncology, 452 Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands, and Department of Oncology, Lund University Hospital, Sweden
    Eur J Cancer 42:3178-85. 2006
    ..Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance...
  13. ncbi [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]
    Farnaz Malekzadeh
    Lunds universitet
    Lakartidningen 102:3226-8, 3230-1. 2005
    ..In conclusion, it is important that doctors discuss the use of CAM and exogenous hormone therapy with their breast cancer patients given the prevalence of these drugs...
  14. ncbi The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate
    Carsten Rose
    Eur J Cancer 40:2859. 2004
  15. ncbi Challenges in the endocrine management of breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Breast 12:S2-19. 2003
    ..These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions..
  16. ncbi Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence
    Anita Ringberg
    Int J Cancer 119:2242-3; author reply 2244. 2006
  17. ncbi "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
    Patrik Edén
    Complex Systems Division, Department of Theoretical Physics, Lund University, Solvegatan 14A, SE 22362 Lund, Sweden
    Eur J Cancer 40:1837-41. 2004
    ..Our analysis suggests that it might be possible to improve the combination of different conventional prognostic markers into one prognostic index...
  18. ncbi Cosmetic outcome and breast morbidity in breast-conserving treatment--results from the Danish DBCG-82TM national randomized trial in breast cancer
    Jørgen Johansen
    Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus
    Acta Oncol 41:369-80. 2002
    ....